---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-019512"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:37:56.709218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones

## Summary
- Upfront payment of $35 million from Immedica upon signing.
- Eligible for aggregate regulatory/commercial milestones up to ~$417 million.
- Royalties in mid-20% range on net sales in certain countries in licensed territory.
- Immedica gets exclusive rights in EUMENA; Actinium retains U.S. and rest-of-world rights.
- Actinium continues to handle clinical development and manufacturing of Iomab-B.

## SEC filing metadata
- accession: 0001213900-22-019512
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/0001213900-22-019512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/ea158381-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-019512
- JSON: https://secwatch.observer/filing/0001213900-22-019512.json
- Plain text: https://secwatch.observer/filing/0001213900-22-019512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.